薬学部
教員紹介
氏名 | 市丸 嘉 |
---|---|
フリガナ(ローマ字) | イチマル ヨシミ(Yoshimi Ichimaru) |
職名 | 講師 |
学位 | 博士(薬学) |
担当授業科目 | 早期臨床体験実習、化学系実習、医療薬学チュートリアル演習Ⅰ、有機化学実習、薬学総合プレ研究、後期臨床体験実習、医療薬学チュートリアル演習Ⅱ、薬局実務実習、卒業研究Ⅰ、卒業研究Ⅱ、総合演習Ⅰ |
専門分野 | 薬化学,分析化学,生物有機化学 |
現在の研究テーマ | 新規抗がん剤の創製:インディルビン誘導体によるキナーゼ阻害活性の応用,新規抗がん剤の創製:金属錯体によるDNA切断活性の応用 等 |
研究内容キーワード | 抗がん剤,金属錯体,X線結晶構造解析,インディルビン,細菌間情報伝達機構 |
研究室紹介 | 薬化学 |
ティーチング・ ポートフォリオ |
|
主な著書・学術論文 | 最新情報はresearchmap(外部サイト)からご確認いただけます。 |
Synthesis and anticancer activity of bis(2-picolyl)amine derivatives with a biaryl moiety as a photosensitizer: Y.Ichimaru,* K. Kato, K. Sogawa, D. Egawa, H. Kato, K. Katakawa, W. Jin, M. Kurihara, H. Kurosaki. Chemistry (2025)7;41. | |
Synthesis and anticancer activity of bis(2-picolyl)amine derivatives with a biaryl moiety as a photosensitizer: Y.Ichimaru,* K. Kato, K. Sogawa, D. Egawa, H. Kato, K. Katakawa, W. Jin, M. Kurihara, H. Kurosaki. Chemistry (2025)7;41. | |
Design, synthesis and characterization of 1-(anthracen-9-ylmethyl)-1,5,9-triazacyclododecane (Ant-[12]aneN3) and its DNA photocleavage activity: Y.Ichimaru,* K. Kato, Y. Yamaguchi, T. Sakamoto, W. Jin, M. Kurihara, M. Fujita, M. Otsuka, H. Kurosaki. Chemical and Pharmaceutical Bulletin (2025)73;103. | |
[1-(Anthracen-9-ylmethyl)-1,4,7,10-tetraazacyclododecane]chloridozinc(II) nitrate: Y.Ichimaru, K. Kato, M. Kurihara, W. Jin, T. Koike, and H. Kurosaki. IUCrData (2024)9;x240665. | |
(5-Fluoro-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-ido-κN1)(1,4,8,11-tetraazacyclotetradecane-κ4N)zinc(II) perchlorate: Y.Ichimaru, K. Kato, M. Kurihara, W. Jin, T. Koike, and H. Kurosaki. IUCrData (2024)9;x240431. | |
Structural Characterization of zinc(II)/cobalt(II) complexes of chiral N-(anthracen-9-yl)methyl-N,N-bis(2-picolyl)amine and evaluation of DNA photocleavage activity: Y.Ichimaru,* K. Kato, R. Nakatani, R. Isomura, K. Sugiura, Y. Yamaguchi, W. Jin, H. Mizutani, M. Imai, M. Kurihara, M. Fujita, M. Otsuka, H. Kurosaki. Chemical and Pharmaceutical Bulletin (2024)71;545. | |
Artificial helix supramolecule by doubly p-xylyl bridged bis(ZnII–cyclen) (cyclen = 1,4,7,10-tetraazacyclododecane): Y.Ichimaru,* K. Kato, K. Sugiura, R. Isomura, H. Fujioka, T. Koike, S. Fujii-Kishida, M. Kurihara, Y. Yamaguchi, W. Jin, M. Imai, H. Kurosaki. Inorganic Chemistry Communications (2023)153;110782. | |
Characterization of Zinc(II) Complex of 1,4,7,10-Tetrazacyclododecane and Deprotonated 5-Fluorouracil (FU) in Crystalline/Solution States and Evaluation of Anticancer Activity: Approach for Improving the Anticancer Activity of FU: Y.Ichimaru, K. Kato, R. Nakatani, K. Sugiura, H. Mizutani, E. Kinoshita-Kikuta, T. Koike, W. Jin, M. Imai, and H. Kurosaki. Inorganic Chemistry Communications (2022)147;110221. | |
Characterization of the Binding of Adenosine-5′-monophosphate to a µ-Type Alkoxide-Linked Dinuclear Zinc(II) Complex in Crystal and Solution State: E. Kinoshita-Kikuta, Y.Ichimaru, Y. Yamano, K. Kato, H. Kurosaki, E. Kinoshita, and T. Koike. Bulletin of the Chemical Society of Japan (2021)94;2670. | |
Crystal Structures of Metallo-β-Lactamase (IMP-1) and Its D120E Mutant in Complexes with Citrate and the Inhibitory Effect of the Benzyl Group in Citrate Monobenzyl Ester: Y. Yamaguchi, K. Kato, Y.Ichimaru, W. Jin, M. Sakai, M. Abe, J. Wachino, Y. Arakawa, Y. Miyagi, M. Imai, N. Fukuishi, Y. Yamagata, M. Otsuka, M. Fujita, and H. Kurosaki. Journal of Medicinal Chemistry (2021)64;10019. | |
Aqua(1,4,7,10-tetraazacyclododecane)zinc(II) bis(perchlorate): Y.Ichimaru, K. Kato, H Kurosaki, H. Fujioka, M. Sakai, Y. Yamaguchi, J. Wanchun, K. Sugiura, M. Imai, and T. Koike. IUCrData (2021)6;x210397. | |
Design and synthesis of an anthranyl bridged optically active dinuclear iron(II)-ligand and evaluation of DNA-cleaving activity: Y.Ichimaru, K. Kato, Y. Okuno, Y. Yamaguchi, W. Jin, M. Fujita, M. Otsuka, M. Imai, and H. Kurosaki. Bioorganic & Medicinal Chemistry Letters (2021)35;127782. | |
Indirubin 3'-oxime inhibits migration, invasion, and metastasis In vivo in mice bearing spontaneously occurring pancreatic cancer via blocking the RAF/ERK, AKT, and SAPK/JNK pathways: Y.Ichimaru, M. Sano, I. Kajiwara, T. Tobe, H. Yoshioka, K. Hayashi, H. Ijichi, and S. Miyairi. Translational Oncology (2019)12;1574. | |
5-Bromoindirubin 3 '-(O-oxiran-2-ylmethyl)oxime: A long-acting anticancer agent and a suicide inhibitor for epoxide hydrolase: Y.Ichimaru, T. Fujii, H. Saito, M. Sano, T. Uchiyama, and S. Miyairi. Bioorganic & Medicinal Chemistry (2017)25;4665. | |
Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo: M. Sano, Y.Ichimaru, M. Kurita, E. Hayashi, T. Homma, H. Saito, S. Masuda, N. Nemoto, A. Hemmi, T. Suzuki, S. Miyairi, and H. Hao. Cancer Letters(2017)397;72. | |
Indirubin 3 '-(O-oxiran-2-ylmethyl)oxime: A novel anticancer agent: Y.Ichimaru, H. Saito, T. Uchiyama, K. Metori, K. Tabata, T. Suzuki, and S. Miyairi. Bioorganic & Medicinal Chemistry Letters (2015)25;1403. |